Current trends in large cell lymphoma (Q35545076)

8 August 2017

1 reference

title

Current trends in large cell lymphoma (English)

1 reference

8 August 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403096

15 March 2024

author name string

R. I. Fisher

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14513044

15 March 2024

P. Shah

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14513044

15 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14513044

15 March 2024

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

https://www.nature.com/articles/2403096.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403096

https://www.nature.com/articles/2403096

15 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403096

15 March 2024

1 reference

8 August 2017

17

1 reference

8 August 2017

1948-1960

1 reference

8 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403096

8 August 2017

0 references

cites work

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Primary mediastinal B-cell lymphoma: a review of pathology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Somatic hypermutation in normal and transformed human B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Control of inflammation, cytokine expression, and germinal center formation by BCL-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Combined modality therapy for localized aggressive lymphoma: enough or too much?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Interpretation of clinical trials in diffuse large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Autologous bone marrow transplantation for patients with poor-prognosis lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Gemcitabine for relapsed or resistant lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

Immunohistological analysis of human lymphoma: correlation of histological and immunological categories.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403096

7 January 2021

Pounding in the neck in supraventricular tachycardia

series ordinal

42

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2403096

15 March 2024

Identifiers

1 reference

8 August 2017

1 reference